BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32001112)

  • 1. Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study.
    Pappolla A; Sánchez F; Caro F; Miguez J; Patrucco L; Cristiano E; Rojas JI
    J Clin Neurosci; 2020 Apr; 74():65-68. PubMed ID: 32001112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown R; Chen J; Atkins HL; Freedman MS; Arnold DL
    Mult Scler; 2018 Jul; 24(8):1055-1066. PubMed ID: 28617152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis.
    Deppe M; Marinell J; Krämer J; Duning T; Ruck T; Simon OJ; Zipp F; Wiendl H; Meuth SG
    Neuroimage Clin; 2014; 6():475-87. PubMed ID: 25610761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis.
    Jakimovski D; Zivadinov R; Bergsland N; Ramasamy DP; Hagemeier J; Weinstock-Guttman B; Kolb C; Hojnacki D; Dwyer MG
    J Neuroimaging; 2020 May; 30(3):342-350. PubMed ID: 32392376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIENA-XL for improving the assessment of gray and white matter volume changes on brain MRI.
    Battaglini M; Jenkinson M; De Stefano N;
    Hum Brain Mapp; 2018 Mar; 39(3):1063-1077. PubMed ID: 29222814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment.
    Koskimäki F; Bernard J; Yong J; Arndt N; Carroll T; Lee SK; Reder AT; Javed A
    PLoS One; 2018; 13(12):e0209326. PubMed ID: 30576361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of gray-matter multiple sclerosis lesions using double inversion recovery, diffusion, contrast-enhanced, and volumetric MRI.
    Parra Corral MA; Govindarajan ST; Stefancin P; Bangiyev L; Coyle PK; Duong TQ
    Mult Scler Relat Disord; 2019 Jun; 31():74-81. PubMed ID: 30951968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of Intracortical Lesions on Volumes of Subcortical Structures in Multiple Sclerosis.
    Kalinin I; Makshakov G; Evdoshenko E
    AJNR Am J Neuroradiol; 2020 May; 41(5):804-808. PubMed ID: 32381540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.
    Fuchs TA; Carolus K; Benedict RHB; Bergsland N; Ramasamy D; Jakimovski D; Weinstock-Guttman B; Kuceyeski A; Zivadinov R; Dwyer MG
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1480-1486. PubMed ID: 29976833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive impairment and memory disorders in relapsing-remitting multiple sclerosis: the role of white matter, gray matter and hippocampus.
    Sacco R; Bisecco A; Corbo D; Della Corte M; d'Ambrosio A; Docimo R; Gallo A; Esposito F; Esposito S; Cirillo M; Lavorgna L; Tedeschi G; Bonavita S
    J Neurol; 2015 Jul; 262(7):1691-7. PubMed ID: 25957638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
    Sotirchos ES; Gonzalez-Caldito N; Dewey BE; Fitzgerald KC; Glaister J; Filippatou A; Ogbuokiri E; Feldman S; Kwakyi O; Risher H; Crainiceanu C; Pham DL; Van Zijl PC; Mowry EM; Reich DS; Prince JL; Calabresi PA; Saidha S
    Mult Scler; 2020 Mar; 26(3):312-321. PubMed ID: 30741108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the effects of white matter multiple sclerosis lesions on the volume estimation of 6 brain tissue segmentation methods.
    Valverde S; Oliver A; Díez Y; Cabezas M; Vilanova JC; Ramió-Torrentà L; Rovira À; Lladó X
    AJNR Am J Neuroradiol; 2015 Jun; 36(6):1109-15. PubMed ID: 25678478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy.
    Lorefice L; Fenu G; Sardu C; Frau J; Coghe G; Costa G; Schirru L; Secci MA; Sechi V; Barracciu MA; Marrosu MG; Cocco E
    Mult Scler; 2019 Jan; 25(1):23-30. PubMed ID: 29111883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study.
    Rocca MA; Preziosa P; Mesaros S; Pagani E; Dackovic J; Stosic-Opincal T; Drulovic J; Filippi M
    Radiology; 2016 Mar; 278(3):841-53. PubMed ID: 26348234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study.
    Horakova D; Dwyer MG; Havrdova E; Cox JL; Dolezal O; Bergsland N; Rimes B; Seidl Z; Vaneckova M; Zivadinov R
    J Neurol Sci; 2009 Jul; 282(1-2):112-9. PubMed ID: 19168190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.
    Zivadinov R; Uher T; Hagemeier J; Vaneckova M; Ramasamy DP; Tyblova M; Bergsland N; Seidl Z; Dwyer MG; Krasensky J; Havrdova E; Horakova D
    Mult Scler; 2016 Nov; 22(13):1709-1718. PubMed ID: 26883943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.